Liquid Biopsy Market Rising at 18% CAGR; Expected to Reach US$ 24.70 Billion by 2033

According to a recent market study by Fact.MR, a leading provider of market research and competitive intelligence, the global market for liquid biopsies has seen significant growth. The market size is estimated at US$ 4.72 billion in 2023 and is projected to grow at a rapid CAGR of 18% to reach US$ 24.70 billion by 2033.

Liquid biopsy technology has emerged as a disruptive force globally. cancer diagnostics that offer non-invasive and highly sensitive approaches to cancer detection and monitoring. This innovative technology has attracted a lot of interest and seen tremendous growth as it has the potential to revolutionize cancer treatment. Liquid biopsies detect cancer biomarkers (such as those obtained from breast biopsies) from physiological fluids such as blood and urine.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9040

In the field of cancer diagnosis and treatment, a pioneering technology known as liquid biopsy is rapidly spreading and revolutionizing cancer detection and monitoring. Liquid biopsy involves the analysis of biomarkers such as circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes, which are secreted by tumors into body fluids such as blood or urine. This non-invasive approach offers several advantages over traditional tissue biopsies, including early detection, real-time monitoring of treatment response, and the possibility of individualized therapy. As this innovative technology gains momentum, the liquid biopsies market is witnessing significant growth and change.

One of the factors driving the liquid biopsies market is the rise in cancer worldwide. As the incidence of cancer increases and early detection is critical to improving patient outcomes, the demand for non-invasive and highly sensitive diagnostic tools increases. Liquid biopsy meets this need by providing a minimally invasive method for the detection of cancer-related biomarkers with high specificity and sensitivity. In addition, liquid biopsy has several advantages over conventional tissue biopsies, which often require invasive procedures and may not always provide representative samples. . A liquid biopsy can be performed more often and in a way with as little discomfort as possible to the patient, allowing real-time monitoring of the course of the disease and the response to treatment. In addition, liquid biopsy allows the detection of tumor heterogeneity, allowing doctors to better understand the genetic makeup of a patient's cancer and adapt treatment strategies accordingly.

The versatility of liquid biopsy extends from cancer detection to many applications, including minimal residual surveillance disease, assessment of treatment response and identification of drug resistance mutations. This versatile approach has led to the use of liquid biopsy in various types of cancer, including lung, breast, colon and prostate cancer.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Bio-Rad Laboratories
Biocept Inc.
Guardant Health
Illumina Inc.
F. Hoffman-La Roche Ltd.
Johnson & Johnson
Laboratory Corporation of America Holdings
MDxHealth SA
QIAGEN N.V
Thermo Fisher Scientific Inc.
QIAGEN;
Myriad Genetics, Inc;
ANGLE plc
Oncimmune
Lucence Health, Inc.
Freenome Holdings, Inc.
Epigenomics AG
Natera, Inc.

𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞:https://www.factmr.com/report/liquid-biopsy-market

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:

The global liquid biopsies market has a variety of companies, from established diagnostic leaders to innovative startups, vying for position in this dynamic field.

Illumina, Inc., known for its genetic sequencing technology, is leading the way by offering significant high performance. sequencing technologies essential for various liquid biopsy procedures.

Guardant Health has rapidly gained recognition and market share for its innovative ctDNA analysis technology that is revolutionizing the detection of cancers.

Biocept specializes in providing comprehensive liquid biopsy testing services that ensure reliable cancer detection and follow-up for patients.

Focused on precision oncology, personal genomic diagnostics (PGDx) offers liquid biopsy solutions that aid in cancer diagnosis and treatment selection, promoting personalized patient care.

Known for its ctDNA testing platform, Natera has made significant advances in prenatal and liquid testing. areas of cancer biopsy that are pushing the boundaries of innovation.

This competitive environment, with established market leaders and innovative new entrants, is conducive to the continued development and expansion of the market, promising exciting advances in cancer diagnosis.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

By Product & Service :
Assay Kits
Instruments
Software and Services

By Circulating Biomarker :
Circulating Tumor Cells (CTCs)
Cell-free DNA
Circulating Cell-free RNA
Exosomes & Extracellular Vesicles
Others

By Indication :
Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Others
Non-cancer
Non-invasive Prenatal Testing (NIPT)
Organ Transplantations
Infectious Disease Testing
Others

By Technology :
Multi-gene-parallel Analysis (NGS)
Single-gene Analysis (PCR Microarrays)

By Clinical Application :
Routine Screening
Patient Work-up
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
Others

By Sample Type :
Blood
Urine
Saliva
Others

By End User :
Hospitals & Laboratories
Specialty Centers
Research Institutes
Others

By Region :
North America
Europe
Latin America
East Asia
South Asia & Oceania
Middle East & Africa

The liquid biopsies market is growing rapidly as revolutionary cancer detection technology gains momentum. Due to its non-invasive nature, high sensitivity and versatility, liquid biopsy is poised to revolutionize cancer diagnosis and treatment, offering new hope to patients and healthcare providers. As research and development progresses, liquid biopsy may revolutionize cancer treatment, ultimately improving patient outcomes and saving lives.

𝐓𝐨𝐩 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲

Blood Collection Tubes for Liquid Biopsy Market
https://www.factmr.com/report/4495/blood-collection-tubes-for-liquid-biopsy-market
Breast Biopsy Marker Market
https://www.factmr.com/report/breast-biopsy-marker-market
Bone Biopsy Systems Market
https://www.factmr.com/report/3884/bone-biopsy-systems-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.